<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05047640</url>
  </required_header>
  <id_info>
    <org_study_id>20210641</org_study_id>
    <nct_id>NCT05047640</nct_id>
  </id_info>
  <brief_title>COVID-19 3rd Dose Vaccine in Transplant Patients</brief_title>
  <official_title>A Single-Blind, Randomized, Controlled Trial Comparing BNT162b2 vs JNJ-78436735 Vaccine as a Booster Dose After Completion of BNT162b2 Vaccine in Solid Organ Transplant Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Giselle Guerra</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Miami</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the efficient vaccine type as a booster dose for&#xD;
      Coronavirus Disease of 2019 (COVID-19) in solid organ transplant recipients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 14, 2021</start_date>
  <completion_date type="Anticipated">December 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Anti-spike protein of SARS-CoV-2 virus IgG positive rate</measure>
    <time_frame>Up to 1 month (post booster vaccination)</time_frame>
    <description>Anti-spike protein of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2) virus Immunoglobulin G (IgG) positivity rate will be assessed from serum blood samples</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of COVID-19 infection</measure>
    <time_frame>Up to 1 month (post infection)</time_frame>
    <description>As assessed by medical records and or patient's report</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with COVID-19 symptom severity as measured by the WHO scale</measure>
    <time_frame>Up to 1 month (post infection)</time_frame>
    <description>World Health Organization (WHO) scale is scored between from 0 -10.&#xD;
0: Uninfected; non-viral Ribonucleic Acid (RNA) detected&#xD;
Asymptomatic; viral RNA detected&#xD;
Symptomatic; Independent&#xD;
Symptomatic; Assistance needed&#xD;
Hospitalized; No oxygen therapy&#xD;
Hospitalized; oxygen by mask or nasal prongs&#xD;
Hospitalized; oxygen by Non-invasive Ventilation (NIV) or High flow&#xD;
Intubation and Mechanical ventilation, partial pressure of oxygen (pO2) /fraction of inspired oxygen (FIO2) &gt;=150 or oxygen saturation (SpO2) /FIO2&gt;=200&#xD;
Mechanical ventilation, (pO2/FIO2&lt;150 OR SpO2/FIO2&lt;200) or vasopressors (norepinephrine &gt;0.3 microg/kg/min)&#xD;
Mechanical ventilation, pO2/FIO2&lt;150 and vasopressors (norepinephrine &gt;0.3 microg/kg/min), or Dialysis or extracorporeal membrane oxygenation (ECMO)&#xD;
Dead</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of vaccine-related adverse events</measure>
    <time_frame>Up to 7 days (post vaccination)</time_frame>
    <description>As assessed by treating physician</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>BNT162b2 vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this arm will receive one booster dose of the BNT162b2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>JNJ-78436735 vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this arm will receive one booster dose of the JNJ-78436735</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BNT162b2 vaccine</intervention_name>
    <description>Single dose of 0.3 mL BNT162b2 vaccine administered intramuscularly in the deltoid muscle</description>
    <arm_group_label>BNT162b2 vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>JNJ-78436735 Vaccine</intervention_name>
    <description>Single dose JNJ-78436735 Vaccine administered intramuscularly in the deltoid muscle</description>
    <arm_group_label>JNJ-78436735 vaccine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients 18 years of age and older&#xD;
&#xD;
          -  Patients who had received a solid organ (kidney, liver, lung, heart, and pancreas)&#xD;
             transplant patient from living or deceased donors.&#xD;
&#xD;
          -  Patients with active graft with at least one immunosuppressive medication&#xD;
&#xD;
          -  Completed two doses of BNT162b2 vaccination at least 28 days ago&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient with non-active graft&#xD;
&#xD;
          -  Any significant side effect with previous COVID-19 vaccination&#xD;
&#xD;
          -  Within 28 days of BNT162b2 vaccine completion&#xD;
&#xD;
          -  Already received more than and equal to three doses of COVID-19 vaccination&#xD;
&#xD;
          -  Previously received COVID-19 vaccine other than BNT162b2 vaccine&#xD;
&#xD;
          -  Previously received monoclonal Antibody treatment&#xD;
&#xD;
          -  History of chronic thrombocytopenia&#xD;
&#xD;
          -  History of Capillary Leak Syndrome&#xD;
&#xD;
          -  Adults unable to consent&#xD;
&#xD;
          -  Individuals who are not yet adults (younger than 18 year old)&#xD;
&#xD;
          -  Vulnerable patients (prisoners)&#xD;
&#xD;
          -  Pregnant women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Giselle Guerra, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Miami</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Giselle Guerra, MD</last_name>
    <phone>3053555803</phone>
    <email>gguerra@med.miami.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lissett Moni, MBA</last_name>
    <phone>3052435235</phone>
    <email>ltueros@med.miami.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giselle Guerra, MD</last_name>
      <phone>305-355-5803</phone>
      <email>gguerra@med.miami.edu</email>
    </contact>
    <contact_backup>
      <last_name>Lissett Moni, MBA</last_name>
      <phone>3052435235</phone>
    </contact_backup>
    <investigator>
      <last_name>Yoichiro Natori, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 13, 2021</study_first_submitted>
  <study_first_submitted_qc>September 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 17, 2021</study_first_posted>
  <last_update_submitted>October 26, 2021</last_update_submitted>
  <last_update_submitted_qc>October 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Miami</investigator_affiliation>
    <investigator_full_name>Giselle Guerra</investigator_full_name>
    <investigator_title>Medical Director of Transplant Services</investigator_title>
  </responsible_party>
  <keyword>transplant patients</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

